OTCMKTS:SGIOY Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Stock Price, News & Analysis $8.72 +0.10 (+1.16%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About Shionogi & Co., Ltd. Unsponsored ADR Stock (OTCMKTS:SGIOY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SGIOY alerts:Sign Up Key Stats Today's Range$8.65▼$8.7650-Day Range$8.24▼$9.0952-Week Range$6.53▼$9.14Volume375,858 shsAverage Volume97,886 shsMarket Capitalization$14.84 billionP/E Ratio14.64Dividend Yield1.72%Price TargetN/AConsensus RatingN/A Company Overview Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan. Read More Shionogi & Co., Ltd. Unsponsored ADR Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreSGIOY MarketRank™: Shionogi & Co., Ltd. Unsponsored ADR scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Shionogi & Co., Ltd. Unsponsored ADR. Earnings and Valuation1.3 / 5Proj. Earnings Growth-1.52% Earnings GrowthEarnings for Shionogi & Co., Ltd. Unsponsored ADR are expected to decrease by -1.52% in the coming year, from $0.66 to $0.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Shionogi & Co., Ltd. Unsponsored ADR is 14.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Shionogi & Co., Ltd. Unsponsored ADR is 14.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.26.Price to Earnings Growth RatioShionogi & Co., Ltd. Unsponsored ADR has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioShionogi & Co., Ltd. Unsponsored ADR has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Shionogi & Co., Ltd. Unsponsored ADR's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Shionogi & Co., Ltd. Unsponsored ADR has been sold short.Short Interest Ratio / Days to CoverShionogi & Co., Ltd. Unsponsored ADR has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shionogi & Co., Ltd. Unsponsored ADR has recently decreased by 18.91%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldShionogi & Co., Ltd. Unsponsored ADR pays a meaningful dividend of 1.78%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthShionogi & Co., Ltd. Unsponsored ADR does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Shionogi & Co., Ltd. Unsponsored ADR will have a dividend payout ratio of 23.08% next year. This indicates that Shionogi & Co., Ltd. Unsponsored ADR will be able to sustain or increase its dividend.Read more about Shionogi & Co., Ltd. Unsponsored ADR's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the float of Shionogi & Co., Ltd. Unsponsored ADR has been sold short.Short Interest Ratio / Days to CoverShionogi & Co., Ltd. Unsponsored ADR has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shionogi & Co., Ltd. Unsponsored ADR has recently decreased by 18.91%, indicating that investor sentiment is improving significantly. News and Social Media1.5 / 5News SentimentN/A News SentimentShionogi & Co., Ltd. Unsponsored ADR has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Shionogi & Co., Ltd. Unsponsored ADR insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.92% of the stock of Shionogi & Co., Ltd. Unsponsored ADR is held by institutions.Read more about Shionogi & Co., Ltd. Unsponsored ADR's insider trading history. Receive SGIOY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. Unsponsored ADR and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGIOY Stock News HeadlinesShionogi Weighs Making Antibiotics in US Amid Rising TariffsAugust 19, 2025 | bloomberg.comSGIOY | Shionogi & Co. Ltd. ADR Annual Balance Sheet - WSJJuly 15, 2025 | wsj.comThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.August 28 at 2:00 AM | Paradigm Press (Ad)Shionogi’s Naldemedine Gains Approval in China for Opioid-Induced ConstipationMay 29, 2025 | tipranks.comShionogi Amends Tender Offer for Torii Pharmaceutical SharesMay 28, 2025 | tipranks.comShionogi Proposes Governance Structure Overhaul to Enhance Strategic OversightMay 16, 2025 | tipranks.comShionogi & Co. Reports Fiscal Year 2024 Financial Results with Positive OutlookMay 12, 2025 | tipranks.comShionogi Expands Pharmaceutical Capabilities with Strategic AcquisitionsMay 7, 2025 | tipranks.comSee More Headlines SGIOY Stock Analysis - Frequently Asked Questions How have SGIOY shares performed this year? Shionogi & Co., Ltd. Unsponsored ADR's stock was trading at $6.9599 at the beginning of 2025. Since then, SGIOY stock has increased by 25.3% and is now trading at $8.72. How were Shionogi & Co., Ltd. Unsponsored ADR's earnings last quarter? Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) announced its earnings results on Monday, July, 28th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.02. The company had revenue of $672.90 million for the quarter, compared to analyst estimates of $719.55 million. How do I buy shares of Shionogi & Co., Ltd. Unsponsored ADR? Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/28/2025Today8/28/2025Next Earnings (Estimated)10/27/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPersonal Services Current SymbolOTCMKTS:SGIOY CIK1281721 Webwww.shionogi.co.jp Phone(166) 202-2161FaxN/AEmployees4,959Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio14.64 Forward P/E Ratio13.21 P/E Growth1.94Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio6.63 Quick Ratio6.13 Sales & Book Value Annual Sales$2.88 billion Price / Sales5.15 Cash Flow$0.75 per share Price / Cash Flow11.62 Book Value$5.29 per share Price / Book1.65Miscellaneous Outstanding Shares1,701,380,000Free FloatN/AMarket Cap$14.84 billion OptionableNot Optionable Beta0.20 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:SGIOY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shionogi & Co., Ltd. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Shionogi & Co., Ltd. Unsponsored ADR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.